文献速递白血病造血干细胞移植与细胞治疗

成人B细胞急性淋巴细胞白血病患者接受贝林妥欧单抗治疗的真实世界结局

Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab.
PubMed 文献 · Blood Adv · 2020-01-01

这项回顾性多中心队列分析纳入239例在临床试验外接受贝林妥欧单抗治疗的成人B细胞急性淋巴细胞白血病患者,其中复发难治227例、微小残留病12例。复发难治患者完全缓解/完全缓解伴计数不完全恢复率为65%(47%微小残留病阴性),中位无复发生存32个月、总生存12.7个月;微小残留病患者9例(75%)达微小残留病阴性。3级及以上细胞因子释放综合征、神经毒性、肝毒性分别为3%、7%、10%。

要点

  • 复发难治患者完全缓解/完全缓解伴计数不完全恢复率65%,其中47%微小残留病阴性。
  • 复发难治患者中位无复发生存32个月,中位总生存12.7个月。
  • 达完全缓解/完全缓解伴计数不完全恢复后行异基因造血干细胞移植巩固对总生存有利(HR 0.54)。

核心结论

  • 在迄今发表的最大真实世界经验中,贝林妥欧单抗显示出与临床试验报告相当的缓解。
  • 急性淋巴细胞白血病中新疗法的优化排序需要进一步研究。

研究设计与样本

  • 回顾性多中心队列分析,纳入239例在临床试验外接受贝林妥欧单抗治疗的急性淋巴细胞白血病患者,其中复发难治227例、微小残留病12例。
  • 贝林妥欧单抗启动时中位年龄48岁(范围18-85岁)。
  • 61例(26%)既往接受≥3线治疗,46例(19%)在贝林妥欧单抗前接受过异基因造血细胞移植。

主要发现

  • 复发难治患者完全缓解/完全缓解伴计数不完全恢复率为65%(47%微小残留病阴性)。
  • 12例因微小残留病接受贝林妥欧单抗的患者中,9例(75%)达微小残留病阴性。
  • 复发难治患者贝林妥欧单抗后中位无复发生存32个月,中位总生存12.7个月。
  • 因微小残留病接受贝林妥欧单抗的患者中位无复发生存未达到(2年时54%微小残留病阴性),总生存34.7个月。
  • 3级及以上细胞因子释放综合征、神经毒性、肝毒性分别见于3%、7%、10%的患者。

局限性

  • 原文结论指出急性淋巴细胞白血病中新疗法的优化排序需要进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The availability and use of blinatumomab symbolizes a paradigm shift in the management of B-cell acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter cohort analysis of 239 ALL patients (227 relapsed refractory [RR], n = 227; minimal residual disease [MRD], n = 12) who received blinatumomab outside of clinical trials to evaluate safety and efficacy in the "real-world" setting. The median age of patients at blinatumomab initiation was 48 years (range, 18-85). Sixty-one (26%) patients had ≥3 prior therapies and 46 (19%) had allogeneic hematopoietic cell transplantation before blinatumomab. The response rate (complete remission/complete remission with incomplete count recovery) in patients with RR disease was 65% (47% MRD-). Among 12 patients who received blinatumomab for MRD, 9 (75%) patients achieved MRD negativity. In patients with RR disease, median relapse-free survival and overall survival (OS) after blinatumomab was 32 months and 12.7 months, respectively. Among patients who received blinatumomab for MRD, median relapse-free survival was not reached (54% MRD- at 2 years) and OS was 34.7 months. Grade ≥3 cytokine release syndrome, neurotoxicity, and hepatotoxicity were observed in 3%, 7%, and 10% of patients, respectively. Among patients who achieved complete remission/complete remission with incomplete count recovery, consolidation therapy with allogeneic hematopoietic cell transplantation retained favorable prognostic significance for OS (hazard ratio, 0.54; 95% confidence interval, 0.30-0.97; P = .04). In this largest "real-world" experience published to date, blinatumomab demonstrated responses comparable to those reported in clinical trials. The optimal sequencing of newer therapies in ALL requires further study.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Badar T, Szabo A, Advani A, et al. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020. PMID: 32453836. doi:10.1182/bloodadvances.2019001381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。